15 completed, 3 not yet recruiting, 1 unknown. 19 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 15, Not yet recruiting 3, Unknown 1 |
| Phase 2 | 6 | Completed 4, Not yet recruiting 1, Unknown 1 |
Follow Malaria, Vivax: new trials by email Literature Review of Malaria, Vivax trials Research Report on Malaria, Vivax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Transmission-Blocking Vaccine Pvs230D1-EPA/Matrix-M in Healthy Malaria-Naive Adults Using a Plasmodium Vivax Controlled Human Malaria Infection and Transmission Model Plasmodium vivax Challenge Agent Derived from PvHMB-CCE001, Pvs230D1-EPA/Matrix-M - Healthy Volunteers, Malaria | Phase 1 / Phase 2 | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 220 | 2026-11-23 | 2026-11-18 |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine | Phase 1 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 72 | 2026-10-01 | 2026-10-22 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax." Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax | Phase 1 | Not yet recruiting | Federal University of Minas Gerais | 48 | 2025-09-01 | 2025-09-15 |
| Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1 PvDBPII/Matrix-M1 - Malaria, Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 24 | 2020-01-24 | 2024-11-25 |
| Plasmodium Immunotherapy for Lung Cancer Blood-stage infection of P. vivax - Lung Cancer, Nonsmall Cell | Phase 1 / Phase 2 | Unknown | State Key Laboratory of Respiratory Disease | 30 | 2016-06-27 | 2023-06-22 |
| P.Vivax Treatment Trial Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ), Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo - Plasmodium Vivax | Phase 1 / Phase 2 | Completed | University of Oxford | 41 | 2016-06-14 | 2022-03-02 |
| A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL - Malaria, Vivax | Phase 1 | Completed | GlaxoSmithKline | 14 | 2016-05-01 | 2017-01-20 |
| Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) Tafenoquine 150 mg, Matched placebo 150mg - Malaria, Vivax | Phase 1 | Completed | GlaxoSmithKline | 486 | 2016-02-02 | 2018-03-01 |
| A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine - Malaria, Vivax | Phase 1 | Completed | GlaxoSmithKline | 120 | 2014-07-31 | 2017-07-13 |
| Phase Ia Study of ChAd63/MVA PvDBP ChAd63 PvDBP 5 x 10^9, ChAd63 PvDBP 5 x 10^10, MVA PvDBP 1 x 10^8 - Malaria, Plasmodium Vivax | Phase 1 | Completed | University of Oxford | 24 | 2013-04-01 | 2017-05-08 |
| Primaquine Pharmacokinetics in Lactating Women and Their Infants Primaquine - Vivax Malaria | Phase 1 | Completed | University of Oxford | 20 | 2012-12-01 | 2016-02-15 |
| Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge P. vivax infected mosquito bites - Malaria | Phase 1 / Phase 2 | Completed | Socrates Herrera Valencia | 16 | 2012-10-01 | 2014-01-15 |
| Tafenoquine Thorough QTc Study in Healthy Subjects Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg - Malaria, Vivax | Phase 1 | Completed | GlaxoSmithKline | 260 | 2011-07-26 | 2017-06-12 |
| Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects A, B - Vivax Malaria | Phase 1 | Completed | University of Oxford | 16 | 2010-10-01 | 2012-06-14 |
| Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults VMP001, P. vivax sporozoite challenge - Malaria, Plasmodium Vivax | Phase 1 / Phase 2 | Completed | U.S. Army Medical Research and Development Command | 41 | 2010-07-01 | 2019-05-29 |
| Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans Malaria Challenge - Plasmodium Vivax Malaria | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 12 | 2009-04-21 | 2018-08-16 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion - Malaria Falciparum, Malaria Vivax | Phase 1 | Completed | Medicines for Malaria Venture | 63 | 2009-04-01 | 2015-01-08 |
| Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants Peptides (N,R&C) formulated in Montanide ISA 720, Peptides (N,R&C) formulated in Montanide ISA 51, Placebo - Malaria, Vivax | Phase 1 | Completed | Malaria Vaccine and Drug Development Center | 40 | 2005-07-01 | 2010-03-08 |
| PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria PpPfs25/ISA51 & ScPvs25/ISA51 - Plasmodium Falciparum, Plasmodium Vivax Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-03-07 | 2017-07-02 |
Malaria (10) · Malaria, Falciparum (3) · Carcinoma, Non-Small-Cell Lung (1) · Parasitemia (1)
Infections (19) · Mosquito-Borne Diseases (19) · Parasitic Diseases (19) · Protozoan Infections (19) · Vector Borne Diseases (19) · Malaria (9) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Inflammation (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
tafenoquine (3) · Primaquine (2) · Artemether, Lumefantrine Drug Combination (1) · Matrix-M (1) · Moxifloxacin (1) · Peptides (1) · artefenomel (1) · artenimol (1) · mannide monooleate (1) · montanide ISA 51 (1)
University of Oxford (5) · GlaxoSmithKline (4) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · U.S. Army Medical Research and Development Command (2) · Federal University of Minas Gerais (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Malaria Vaccine and Drug Development Center (1) · Medicines for Malaria Venture (1) · Socrates Herrera Valencia (1) · State Key Laboratory of Respiratory Disease (1)
United States (9) · Colombia (2) · Thailand (2) · United Kingdom (2) · Australia (1) · Brazil (1) · China (1) · Laos (1)
Adrian V S Hill, MD (1) · Angela M Minassian, Dr (1) · Ilin Chuang, MD, MPH (1) · Jason Bennett, MD (1) · Joerg Moehrle, PhD (1) · Maria Gutierrez, MD (1) · Mayfong Mayxay, MD (1) · Ming Ou-Yang, M.D. (1) · Myriam Arevalo-Herrera, PhD (1) · Podjanee Jittamala, MD (1) · Ricardo T Gazzinelli, DVM, PhD (1) · Rose McGready, MD (1) · Shanan R Immel, M.D. (1)
PMID 18612426, PMID 21931708, PMID 22759078, PMID 24088113, PMID 24687509, PMID 24963662, PMID 27697758, PMID 28614791, PMID 29590311, PMID 29869298, PMID 31187437, PMID 31888643, PMID 31900172, PMID 34161579, PMID 35664997, PMID 38719803